JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kassis, A. I.
Right arrow Articles by Adelstein, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kassis, A. I.
Right arrow Articles by Adelstein, S. J.

Radiobiologic Principles in Radionuclide Therapy

Amin I. Kassis, PhD; and S. James Adelstein, MD, PhD

Department of Radiology, Harvard Medical School, Boston, Massachusetts



View larger version (15K):

[in a new window]
 
FIGURE 1. Number of radioactive atoms needed to assure traversal of cell nucleus by a single energetic particle as function of distance from nuclear membrane. Nuclear-to-cell radius (percentage) plotted as function of number of decays in cell membrane.

 


View larger version (35K):

[in a new window]
 
FIGURE 2. Rate of energy loss of electrons as function of traversed distance.

 


View larger version (109K):

[in a new window]
 
FIGURE 3. Local density of ionizations (*) produced along track (_) of energetic ß-particles, Auger electrons, and {alpha}-particles.

 


View larger version (21K):

[in a new window]
 
FIGURE 4. Survival of mammalian cells after high- or low-LET irradiation.

 


View larger version (16K):

[in a new window]
 
FIGURE 5. Bystander effect observed in vivo in mouse adenocarcinoma model. Human colon LS174T adenocarcinoma cells were prelabeled with lethal doses of DNA-incorporated 125I-UdR, mixed with unlabeled cells at ratios indicated, and injected subcutaneously in mice. Bystander effect is indicated by percentage growth inhibition in vivo of unlabeled cells.

 


View larger version (16K):

[in a new window]
 
FIGURE 6. (A) Schematic representation of mammalian-cell survival curves after uniform irradiation with {alpha}- and ß-particles (solid lines) and departure from exponential decrease when radionuclides are not uniformly distributed (broken lines) (10). (B) Survival of mammalian cells exposed in suspension to 211At-astatide or 211At-UdR (only 50% of cells labeled) (2,14).

 


View larger version (27K):

[in a new window]
 
FIGURE 7. Therapeutic impact of nonuniform tumor-dose distribution. Surviving fraction plotted as function of nonuniformity for differing mean absorbed doses (11).

 


View larger version (40K):

[in a new window]
 
FIGURE 8. Percentage change in median survival of ovarian-cancer-bearing mice treated with {alpha}- or ß-particle-emitting radiocolloids (16).

 


View larger version (17K):

[in a new window]
 
FIGURE 9. Induction of hind leg paralysis in rats by intrathecally growing human tumor cells after saline or methorexate–125I-UdR treatment.

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.